Orion Corporation
↗Espoo, Finland
Orion Corporation is a globally operating Finnish pharmaceutical company founded in 1917, headquartered in Espoo, Finland. The company develops, manufactures, and markets human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs).
Orion focuses its pharmaceutical R&D primarily on oncology and pain management, while also maintaining a portfolio of proprietary drugs, generic medicines, and consumer health products. The company has a strong international presence, with products available in over 100 countries and manufacturing facilities primarily located in Finland.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:€1.89B
Founded:1917
Ownership:public
Status:operating
STOCK
Exchange:Nasdaq Helsinki
Ticker:ORNAV, ORNBV
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Antibody therapeutics
Active Trials:135
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Fermion Oy
Key Partnerships:Bayer (Nubeqa/darolutamide), MSD/Merck (Opevesostat, ODM-208), Tenax Therapeutics (Levosimendan), Abilita Therapeutics (Antibody discovery)
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Liisa Hurme - President and CEO
LINKS
Website:orionpharma.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Orion Corporation and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Orion Corporation. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.